Disease State Plasma Samples for Biomarker and Diagnostic Research
Disease state plasma captures the circulating molecular signatures of active disease—proteins, nucleic acids, autoantibodies, metabolites, and other analytes that differ meaningfully from healthy donor plasma and reflect underlying pathology, treatment effects, and disease progression. MT Group provides human disease state plasma from carefully characterized patient populations across oncology, autoimmune, metabolic, and other therapeutic areas. Our prospective collection model means disease state plasma samples are collected with the specific anticoagulants, processing protocols, clinical annotation, and timepoint schedules your study requires—not retrofitted from an existing inventory.
Disease State Plasma Samples for Biomarker and Diagnostic Research
Disease state plasma captures the circulating molecular signatures of active disease—proteins, nucleic acids, autoantibodies, metabolites, and other analytes that differ meaningfully from healthy donor plasma and reflect underlying pathology, treatment effects, and disease progression. MT Group provides human disease state plasma from carefully characterized patient populations across oncology, autoimmune, metabolic, and other therapeutic areas. Our prospective collection model means disease state plasma samples are collected with the specific anticoagulants, processing protocols, clinical annotation, and timepoint schedules your study requires—not retrofitted from an existing inventory.
Why Disease State Plasma Requires
a Different Approach Than Healthy Donor Plasma
Disease state plasma for research demands more than a tube of blood and a diagnosis code. The research value of disease state plasma samples depends on precise clinical context: What stage is the disease? What treatments have the patient received, and how have they responded? Are comorbidities present that could confound biomarker analysis? Is the sample from a pre-treatment baseline, an active therapy timepoint, or a post-progression draw?
MT Group designs disease state plasma collections around these variables because they determine whether your specimens produce meaningful data or noise. Every collection begins with a detailed study design consultation where we define enrollment criteria, clinical data requirements, and processing specifications before a single tube is drawn. This is the same consultative approach that has driven over 90% subject retention in our longitudinal disease state plasma studies and earned us the trust of pharmaceutical, biotechnology, and laboratory diagnostics companies since 2003.
Disease State Plasma Collection Capabilities
MT Group collects disease state plasma from diverse patient populations across our established site network. Below are the therapeutic areas we most commonly support, though our prospective collection model allows us to activate collections for conditions beyond those listed here.
Oncology
Disease state plasma from cancer patients is among our most requested specimen types, supporting liquid biopsy development, circulating tumor DNA (ctDNA) analysis, minimal residual disease (MRD) detection, immunotherapy biomarker research, and companion diagnostic validation. We collect oncology plasma across solid tumors including lung (NSCLC and SCLC), breast, colorectal, pancreatic (PDAC), hepatocellular carcinoma (HCC), ovarian, prostate, bladder, renal cell carcinoma, and glioblastoma (GBM), as well as hematologic malignancies. Collections can be stratified by treatment status (treatment-naïve, on-therapy, post-progression), specific therapeutic regimens, and molecular subtypes when documented in the clinical record.
Autoimmune and Inflammatory Disease
Disease state plasma from patients with autoimmune conditions supports autoantibody profiling, cytokine analysis, immune cell biomarker discovery, and therapeutic target identification. Conditions include rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), multiple sclerosis, psoriatic arthritis, and other immune-mediated disorders. Collections can be designed around disease activity scores (DAS-28, PASI, EASI, Mayo Score), treatment history including biologic-naïve and biologic-experienced populations, and washout status.
Metabolic Disease
Human disease state plasma from patients with metabolic conditions including Type 1 and Type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD/NASH), thyroid disorders, dyslipidemia, and obesity. These collections support metabolomics studies, glucose and insulin metabolism research, lipid profiling, and biomarker validation for disease monitoring and therapeutic development. Clinical annotation commonly includes HbA1c levels, fasting glucose, lipid panels, BMI, and medication histories.
Neurological Conditions
Plasma collections from patients with neurological and neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, multiple sclerosis, schizophrenia, bipolar disorder, generalized anxiety disorder, major depressive disorder, and neuropathic pain syndromes. Disease state plasma for neurological research increasingly supports blood-based biomarker discovery as an alternative to cerebrospinal fluid collection, with applications in neurofilament light chain (NfL), phosphorylated tau, and other emerging circulating neuro-biomarkers.
Cardiovascular Disease
Disease state plasma from patients with cardiovascular conditions including heart failure, atrial fibrillation, coronary artery disease, and post-myocardial infarction. Collections support troponin research, NT-proBNP studies, lipid biomarker validation, and cardiovascular drug development programs.
Other Conditions
MT Group's prospective collection model is not limited to the categories above. We regularly activate disease state plasma collections for respiratory conditions (COPD, asthma, IPF), renal disease, ophthalmologic conditions, rare diseases, and other therapeutic areas based on site feasibility and patient population access. Contact us to discuss your specific disease state plasma requirements.
Disease State Plasma
Processing Protocols
The downstream application of disease state plasma dictates how it must be collected and processed. MT Group customizes every aspect of plasma processing to your study specifications, and our sites are experienced in executing complex protocols consistently across subjects.
Anticoagulant Selection
Different research applications require different anticoagulant systems. MT Group collects disease state plasma in the tube type that matches your analytical platform:
EDTA Plasma: The most commonly requested anticoagulant for general biomarker work, proteomic analysis, and immune profiling. EDTA effectively chelates calcium to prevent coagulation and preserves most protein and nucleic acid analytes.
Streck Cell-Free DNA BCT Tubes: Required for circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) applications. Streck tubes contain proprietary preservatives that stabilize nucleated blood cells and prevent genomic DNA contamination of the cell-free fraction—critical for liquid biopsy applications where even minor white blood cell lysis can overwhelm the ctDNA signal.
Citrate Plasma: Used for coagulation studies and certain immunoassay platforms. Citrate reversibly binds calcium, making it the standard for functional coagulation testing.
Heparin Plasma: Preferred for certain metabolomics and clinical chemistry applications. Lithium heparin and sodium heparin tubes are available based on study requirements.
Specialized Tubes: PAXgene RNA tubes for circulating RNA stabilization, ACD tubes for cell viability preservation, and other specialized collection systems are available as needed.
Centrifugation Protocols
Single-Spin Centrifugation: Standard processing for most disease state plasma applications. Centrifugation parameters (speed, duration, temperature) are specified in your collection SOP.
Double-Spin Centrifugation: MT Group was among the first biospecimen suppliers to offer double-spin protocols, recognizing the considerable benefits for producing platelet-poor plasma. The second centrifugation step removes residual platelets and cellular debris that can interfere with sensitive downstream assays. Double-spin is strongly recommended for liquid biopsy, cfDNA, exosome, and extracellular vesicle applications.
Aliquoting and Storage
Disease state plasma is aliquoted according to your specifications—volume per aliquot, number of aliquots per subject, and tube type are all customizable. Specimens are stored at -20°C or -80°C depending on analyte stability requirements and shipped on dry ice to maintain the cold chain from collection site to your laboratory.
Clinical Annotation for
Disease State Plasma
The research value of disease state plasma samples depends as much on the clinical data accompanying them as on the specimens themselves. MT Group provides comprehensive, validated clinical annotation that goes well beyond a diagnosis and demographic summary.
Standard Clinical Data Elements
Every disease state plasma collection includes demographics (age, sex, race/ethnicity, BMI), primary diagnosis with date of diagnosis, complete medical history and relevant comorbidities, current and prior treatment history with dates, dosing, and duration, concomitant medications, and lifestyle factors including smoking status and alcohol use. Additional standard laboratory values and clinical assessments collected as part of the patient's routine care are captured on customized case report forms.
Disease-Specific Annotation
Disease state plasma for research often requires annotation tailored to the therapeutic area:
Oncology: Cancer stage and grade, tumor molecular subtype (when documented), prior lines of therapy, specific regimens and dates, progression dates, and surgical history.
Autoimmune: Disease activity scores (DAS-28, PASI, EASI, Mayo Score, CDAI), biologic treatment history, washout status, flare frequency, and duration of disease.
Metabolic: HbA1c, fasting glucose, lipid panels, BMI trends, insulin use, and oral medication history.
Treatment Response and Outcome Data
For prospective and longitudinal disease state plasma collections, MT Group captures treatment response data when available through standard-of-care follow-up. This includes response classifications, progression events, treatment changes, and clinical outcomes. This longitudinal clinical context transforms disease state plasma samples from isolated snapshots into connected datasets that support biomarker-outcome correlation studies.
Data Validation
MT Group's dedicated clinical data team reviews every case report form for completeness, internal consistency, and accuracy before specimens are released. Discrepancies between clinical data elements—such as a treatment history that conflicts with a stated diagnosis or timeline—are resolved directly with the clinical site. This validation step ensures that the clinical annotation accompanying your disease state plasma is reliable and research-ready.
Longitudinal Disease State
Plasma Collections
Tracking biomarker changes over time requires specimens collected at defined intervals from the same patients. MT Group has built its reputation on longitudinal disease state plasma collections, achieving over 90% subject retention across multi-timepoint studies. This retention rate reflects strong site relationships, proactive subject management, and collection schedules designed around existing standard-of-care visit patterns to minimize patient burden.
Longitudinal disease state plasma collections are particularly valuable for:
Treatment response monitoring: Pre-treatment baseline, on-therapy timepoints, and post-treatment follow-up to track biomarker dynamics across the treatment arc
Disease progression studies: Serial plasma draws that capture the molecular evolution of disease over months or years
Minimal residual disease (MRD) detection: Post-treatment surveillance plasma to monitor for disease recurrence through ctDNA or other circulating biomarkers
Vaccine and immunotherapy response: Tracking immune responses at defined intervals following therapeutic intervention
Matched Specimen Collections
Disease state plasma can be collected alongside matched biospecimens from the same subjects and timepoints, including whole blood, serum, buffy coat, urine, and—when the clinical setting permits—tissue biopsies. Matched plasma-tissue collections are especially valuable for validating circulating biomarkers against tissue-based findings.
Why Choose MT Group
for Disease State Plasma
Consultative Study Design: MT Group does not simply accept orders for disease state plasma samples. We ask detailed questions to fully understand your study objectives, analytical platforms, and clinical data requirements before designing a collection protocol. This upfront investment in study design prevents costly downstream problems caused by specimens that don't meet your actual research needs.
Realistic Feasibility Assessment: We conduct thorough site feasibility evaluations to provide honest projections about enrollment potential and timelines. We frequently take over disease state plasma collections that other CROs have abandoned after overpromising and underdelivering, getting stalled studies back on track. By setting accurate expectations from the start, MT Group protects your research timelines and budget.
Proven Longitudinal Expertise: With over 90% subject retention rates in multi-timepoint studies, MT Group has demonstrated the operational discipline required for longitudinal disease state plasma collections. Our project management team provides weekly study updates and detailed collection notifications that make accessioning straightforward for your laboratory team.
Rigorous Quality and Data Validation: Every disease state plasma specimen undergoes quality review before release, including hemolysis assessment, volume verification, and labeling confirmation. Our clinical data team independently validates all annotation for completeness and internal consistency. If any specimen fails to meet agreed-upon specifications, we replace it at no additional cost.
Two Decades of Experience: MT Group has supported disease state plasma collections for pharmaceutical, biotechnology, and diagnostics companies since 2003. This depth of experience means our sites understand the critical importance of following detailed collection protocols and our project teams know how to anticipate and resolve enrollment challenges before they impact your timelines.
Why Leading Researchers Choose MT Group
Frequently Asked Questions About Disease State Plasma
What disease state plasma samples are available?
MT Group provides disease state plasma across oncology (lung, breast, colorectal, pancreatic, liver, ovarian, prostate, bladder, renal, GBM, and hematologic malignancies), autoimmune and inflammatory diseases (rheumatoid arthritis, lupus, psoriasis, IBD, multiple sclerosis), metabolic conditions (diabetes, NASH, metabolic syndrome), neurological conditions, cardiovascular disease, and other therapeutic areas. Our prospective collection model allows us to activate new disease state plasma collections based on your specific requirements and site feasibility.
How are disease state plasma specimens annotated?
Disease state plasma specimens are accompanied by comprehensive clinical documentation including demographics, diagnosis with date, complete treatment history with regimens and response data, comorbidities, concomitant medications, lifestyle factors, and relevant laboratory values. Disease-specific annotation such as cancer staging, disease activity scores, viral load data, or metabolic panels is captured on customized case report forms. All clinical data is validated by MT Group's dedicated data team for completeness and internal consistency before specimens are released.
What anticoagulants are available for disease state plasma?
MT Group collects disease state plasma in EDTA, Streck Cell-Free DNA BCT, citrate, heparin (lithium and sodium), ACD, PAXgene RNA, and other specialized collection tubes based on your analytical requirements. Anticoagulant selection is specified during study design to match your downstream research platform.
What processing options are available for disease state plasma?
Processing protocols are fully customizable and include single-spin and double-spin centrifugation at specified speeds, durations, and temperatures. MT Group was among the first biospecimen suppliers to offer double-spin protocols for producing platelet-poor plasma, which is strongly recommended for liquid biopsy and cfDNA applications. Aliquot volumes, aliquot counts per subject, tube types, and storage temperatures (-20°C or -80°C) are all specified in your collection SOP.
Can disease state plasma be collected at multiple timepoints from the same patient?
Yes, longitudinal multi-timepoint collections are a core specialty. MT Group achieves over 90% subject retention in longitudinal disease state plasma studies by designing collection schedules around standard-of-care visit patterns and maintaining strong site-subject relationships. Timepoints are defined during study design and can include pre-treatment baselines, on-therapy draws, post-treatment surveillance, and disease progression events.
How is disease state plasma different from healthy donor plasma?
Disease state plasma reflects active pathology—circulating tumor DNA, elevated cytokines, autoantibodies, altered metabolite profiles, and other analytes that are absent or present at different concentrations in healthy donors. Critically, the clinical annotation requirements are substantially different: disease state plasma for research requires detailed treatment histories, disease staging, response data, and comorbidity profiles that healthy donor plasma does not. MT Group's disease-specific case report forms capture this clinical context to ensure your specimens support meaningful translational research.
Can disease state plasma be matched with other specimen types?
Yes, disease state plasma is routinely collected alongside matched whole blood, serum, buffy coat, and urine from the same subjects and timepoints. When the clinical setting permits, matched tissue biopsies can also be collected. Matched specimen sets enable tissue-plasma biomarker correlation studies and multi-omic research approaches.
What is the turnaround time for disease state plasma collections?
Prospective disease state plasma collections typically begin 2-4 weeks after receiving a purchase order. During this period, MT Group develops a collection SOP, assembles study-specific material kits, and onboards collection sites. Nearly all collections fit under established umbrella IRB protocols, eliminating the need for additional approvals. Enrollment timelines depend on your specific eligibility criteria and disease population.
Contact MT Group
Complete the form below to discuss your tissue requirements with our experts.
No obligation consultation. Response within one business day.
